Public deck

Axsome Therapeutics: the neuroscience growth story still has to outrun losses and cash burn

AXSM has an annual revenue baseline of $638.5M, latest revenue marker of $191.2M Q1 2026, annual net income of -$183.2M and cash of $305.1M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.